SCHEMBL136480

SCHEMBL136480

Nc1sc2c(c1C(=O)c1ccccc1F)CCCC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
ALDH1A1 P00352 5/20 0.68
HPGD P15428 3/20 0.68
LMNA P02545 2/20 0.68
GAA P10253 1/20 0.68
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ADORA1 P30542 1/20 0.54
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 2/20 0.54
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
MAPK10 P53779 1/20 0.51
TAAR1 Q96RJ0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31502652 0.86 ALDH1A1 (0.72) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL29207627 0.85 MAPT (0.66) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL136157 0.84 ALDH1A1 (0.68) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL30133117 0.83 ALDH1A1 (0.63) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL5678880 0.82 ALDH1A1 (0.65) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL8289393 0.82 MAPT (0.65) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL1637546 0.81 ALDH1A1 (1.00) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL10447284 0.81 ALDH1A1 (0.64) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL5851585 0.80 ALDH1A1 (0.97) MAPTALDH1A1HPGDLMNAGAA
SCHEMBL5675390 0.79 ALDH1A1 (0.61) MAPTALDH1A1HPGDLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430029-B1 THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS UNIV LEUVEN KATH (BE) 2018-01-10 EP disclosed
US-9499563-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2016-11-22 US disclosed
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS CISTIM LEUVEN VZW (BE) 2014-10-02 US disclosed
US-8785638-B2 Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2014-07-22 US disclosed
EP-2430029-A1 THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS Katholieke Universiteit Leuven (BE) 2012-03-21 EP disclosed
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2012-03-08 US disclosed
WO-2010130842-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2010-11-18 WO disclosed
US-3957783-A URICOSURIC ACTIVITY SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296272-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS MAPT 2061/4885ALDH1A1 1925/4885HPGD 466/4885
US-20120059028-A1 THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS TYMP, DUT, MAVS MAPT 2061/4885ALDH1A1 1925/4885HPGD 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.